Statement from the Commander 1 Canadian Air Division

On the same subject

• 

  September 15, 2020 | Local, Land

  B-Temia gagne en force aux États-Unis

  La firme a obtenu le feu vert de la Food and Drug Administration pour commercialiser son exosquelette L'entreprise B-Temia décroche les autorisations nécessaires pour commercialiser son exosquelette aux États-Unis et n'écarte pas la possibilité d'y ouvrir une usine de production. Par ailleurs, la direction a des discussions pour un possible contrat avec l'armée suisse. Hier, la Food and Drug Administration (FDA) a donné le feu vert à la compagnie de Québec pour vendre son système dermosquelette d'assistance à la marche motorisé Keeogo aux personnes ayant des limitations physiques en raison de problèmes de santé. « Les États-Unis représentent plus de 50 % du marché mondial pour ce type d'appareil. C'est majeur, nous allons avoir accès à plus de la moitié de la tarte », note Stéphane Bédard, président et chef de la direction de B-Temia. Cette dernière compte 35 employés dans le monde, dont une vingtaine au Québec. La compagnie a également une division en Asie en partenariat avec Wistron Corporation. Le siège social est à Singapour. Déjà aux États-Unis Mentionnons que dans le cadre d'un partenariat signé en 2018 avec l'entreprise Lockheed Martin, B-Temia travaillait déjà sur certains produits destinés à l'armée américaine. « Le dossier militaire fait intervenir des personnes saines. Lorsque les gens n'ont pas de maladie, la FDA n'intervient pas. Le même produit peut être utilisé pour d'autres objectifs que de restaurer la démarche », dit M. Bédard. L'exosquelette développé pour les militaires améliore notamment leur performance lorsqu'ils doivent transporter de l'équipement sur une plus longue période et aide à prévenir les blessures, avance le président. L'appareil en question fournit une force supplémentaire aux genoux. Gr'ce à l'autorisation de la FDA, B-Temia prévoit prendre de l'expansion au cours des prochaines années, entre autres à Québec où plus de 10 millions $ devraient être injectés. Des embauches seront aussi effectuées. L'entreprise était en discussion avec la FDA depuis 2016. La direction souligne également son intention de poursuivre ses démarches pour obtenir les approbations réglementaires nécessaires dans d'autres pays. Plusieurs projets en chantier Quant à l'expansion au sud de la frontière canadienne, B-Temia, qui a été fondée en 2010, analyse différents scénarios. Comme pour l'Asie, cette offensive pourrait se faire avec l'aide d'un partenaire d'affaires. « On veut rendre accessible le plus rapidement cette technologie à travers le monde. Oui, on pourrait avoir des activités directes sur le territoire américain. Le modèle d'affaires pour les États-Unis est à l'étude », affirme M. Bédard, précisant ne pas avoir d'échéancier à fournir pour le moment. Par ailleurs, « l'armée suisse fait également des essais avec nos produits. Nous avons aussi d'autres projets militaires sur la table », conclut-il. Afin d'appuyer sa croissance, la direction de B-Temia n'écarte pas la possibilité de faire le saut à la Bourse d'ici cinq ans. Le produit développé par B-Temia, qui est aussi commercialisé au Canada, pourrait notamment servir pour améliorer la démarche des patients ayant subi un AVC. https://www.journaldequebec.com/2020/09/15/b-temia-gagne-en-force-aux-etats-unis

• 

  January 26, 2018 | Local, Naval

  Weapons system support contract to help protect Canadian ships, sailors

  News Release From National Defence January 26, 2018 – Esquimalt, B.C. – National Defence / Canadian Armed Forces The Government of Canada is committed to providing the women and men of the Canadian Armed Forces with the equipment they need, as outlined in Canada's new defence policy, Strong, Secure, Engaged. Today, the Honourable Harjit S. Sajjan, Minister of National Defence, announced the award of a contract in support of weapons systems that will protect Canadian ships and sailors over the next two decades. Valued at $704 million, this contract will also benefit Canadians, as it is expected to create and maintain more than 450 well-paid, skilled jobs across the country. Under this contract, Raytheon Canada Limited will upgrade and support 21 Close-In Weapons Systems for the Royal Canadian Navy. These rapid-fire, radar-guided gun systems provide the most effective naval self-defence system available against close-in threats such as missiles, small ships, and aircraft. These systems are currently in use on the Navy's Halifax-class frigates, and will also be installed on the Protecteur-class joint support ships following their construction. Quotes “Today's announcement is aligned with the goals we set out in Strong, Secure, Engaged – we are making strategic investments in the Royal Canadian Navy that will help protect our sailors as they conduct the full spectrum of operations in a modern security environment.” – Minister of National Defence, Harjit S. Sajjan “As a result of the government's ITB policy, Raytheon Canada Limited will make important investments in Canada to support well-paying, middle class jobs, foster economic growth and help spur innovation across the country in small and medium enterprises. That's how we ensure innovation works for all Canadians.” – Innovation, Science and Economic Development Minister Navdeep Bains Quick Facts The Close-In Weapon System (CIWS) In-Service Support contract will be valid until late 2037, and comprises an initial 10-year service period with three options of five, three and two additional years, respectively. The CIWS is the world's most widely deployed close-in weapons system and currently in service with 24 nations. This level of interoperability will allow the Navy to take advantage of future improvements made by our allies. The Industrial and Technological Benefits Policy (ITB), including the Value Proposition, applies to this contract and will support the growth of a sustainable Canadian defence and marine industry. In addition, Raytheon Canada Limited has committed to investing in Canadian small and medium-sized enterprises and research and development activities. Contacts Byrne Furlong Press Secretary Office of the Minister of National Defence Phone: 613-996-3100 Media Relations Department of National Defence Phone: 613-996-2353 Toll-Free: 1-866-377-0811 Email: mlo-blm@forces.gc.ca https://www.canada.ca/en/department-national-defence/news/2018/01/weapons_system_supportcontracttohelpprotectcanadianshipssailors.html

• 

  November 7, 2018 | Local, Aerospace

  Magellan Awarded CDN $140 Million Contract Extension with Airbus

  Toronto, Ontario – 5 November 2018 -- Magellan Aerospace Corporation (“Magellan”) announced today, that they have secured a six year agreement with Airbus for a contract extension for the manufacture of A350 XWB centre wing box and keel beam detail parts. It is estimated that revenue generated from this work package will exceed CDN $140 million dollars over the term of the contract. The package consists of a number of large structural, machined components, and will be manufactured by Magellan in the United Kingdom and supplied to the Airbus assembly facility in Nantes, France. Mr Haydn Martin, Magellan's Vice President, New Business Development said, “This contract extension has been achieved through a combination of demonstrated operational excellence and market competitive pricing. As a strategic partner to the Airbus Group, Magellan continues to align our technology investments and manufacturing best practices to meet their current and future requirements. About Magellan Aerospace Corporation Magellan Aerospace Corporation is a global aerospace company that provides complex assemblies and systems solutions to aircraft and engine manufacturers, and defense and space agencies worldwide. Magellan designs and manufactures aeroengine and aerostructure assemblies and components for aerospace markets, advanced proprietary products for military and space markets, and provides engine and component repair and overhaul services worldwide. Magellan is a public company whose shares trade on the Toronto Stock Exchange (TSX: MAL), with operating units throughout North America, Europe, and India. Forward Looking Statements Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. When used herein, words such as "expect", "anticipate", "estimate", "may", "will", "should", "intend", "believe", and similar expressions, are intended to identify forward-looking statements. Forward-looking statements are based on estimates and assumptions made by the Corporation in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Corporation believes are appropriate in the circumstances. Many factors could cause the Corporation's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including those described in the "Risk Factors" section of the Corporation's Annual Information Form (copies of which filings may be obtained at www.sedar.com). These factors should be considered carefully, and readers should not place undue reliance on the Corporation's forward-looking statements. The Corporation has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. For information: Laura Podaima Director, Corporate Communications Magellan Aerospace Ph. 204 788 2831 laura.podaima@magellan.aero http://magellan.aero/investors/press-releases/